Skip to main content
S&P 5007,561.67-0.40%DOW52,347.55+0.10%NASDAQ25,136.27-0.91%BTC$68,208.00-4.63%ETH$1,926.53-4.56%GOLD$3,877.50-0.20%OIL$89.23+0.55%
Smart Investors Daily
SID Premium
DR

NASDAQ · DRMA

Dermata Therapeutics, Inc.

Healthcare · Biotechnology

$0.66

Down-$0.04 (-6.01%)

Updated Nov 13, 2026, 9:52 PM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.9M
P/E ratio
-0.32
Dividend yield
0.00%
52-week range
$0.60 – $4.66
Volume
15.51K
Avg. volume
196.69K

Price performance · DRMA

DRMA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 12, 2026

DRMA closed at $0.66 after 21 trading sessions, down 27.37% for the selected period.

Last close
$0.66
Period change
-27.37%
Period low
$0.66
Period high
$0.91
Daily close
View OHLC price history
DRMA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 12, 2026$0.7088$0.7088$0.6601$0.660915.51K
Nov 11, 2026$0.74$0.74$0.6503$0.71582.77K
Nov 10, 2026$0.75$0.778$0.7135$0.714545.21K
Nov 9, 2026$0.7818$0.8129$0.7192$0.7736.73K
Nov 6, 2026$0.757$0.8357$0.7302$0.76460.21K
Nov 5, 2026$0.85$0.85$0.7617$0.761950.62K
Nov 4, 2026$0.8444$0.8696$0.8032$0.854851.99K
Nov 3, 2026$0.7565$0.9094$0.7201$0.8487226.04K
Nov 2, 2026$0.7708$0.8193$0.744$0.7538141.37K
Oct 30, 2026$0.799$0.829$0.7632$0.77562.2K
Oct 29, 2026$0.88$0.88$0.8211$0.841132.22K
Oct 28, 2026$0.77$0.8904$0.7501$0.8747169.92K
Oct 27, 2026$0.736$0.7697$0.6727$0.755188.39K
Oct 26, 2026$0.759$0.78$0.7033$0.718114.63K
Oct 23, 2026$0.8331$0.8497$0.7717$0.781124.96K
Oct 22, 2026$0.78$0.87$0.78$0.864140.28K
Oct 21, 2026$0.8501$0.8898$0.7817$0.7995222.82K
Oct 20, 2026$0.8554$0.9275$0.83$0.8699185.13K
Oct 19, 2026$0.8478$0.9701$0.76$0.8599852.47K
Oct 16, 2026$0.909$0.9504$0.81$0.862.52M
Oct 15, 2026$0.7685$1.18$0.7658$0.91170.52M

Latest DRMA news

The latest Smart Investors Daily articles mentioning DRMA.

Stock researchCompany · Overview

DRMA research

Overview

Company profile and research snapshot.

Company profile

Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$6.00
Implied upside
—
Analysts
—
DRMA recent ratings
DateFirmRatingTarget
Aug 21, 2025Maxim GroupBuy—
May 21, 2025Maxim GroupBuy—
Aug 21, 2024Maxim GroupBuy—
Mar 23, 2023Maxim GroupBuy—
Sep 21, 2021Brookline CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 5, 2026

Dermata Therapeutics Highlights Media Recognition of Tome Skincare Following Commercial Launch

\- Tome Skincare featured in Cosmopolitan, Women's Wear Daily, AIR MAIL, and Thingtesting highlights Tome's growing recognition among leading beauty editors -SAN DIEGO, CA / ACCESS Newswire / November 5, 2026 / , Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent editorial coverage of its Tome skincare brand across multiple beauty publications surrounding the commercial launch of Tome Foundational Treatment on August 25, 2

Yahoo · Oct 29, 2026

Dermata Advances Second Tome Skincare Product Toward Expected 2027 Launch with Initiation of Acne Clinical Trial

\- Tome Clearing Treatment is Dermata's second once-weekly skincare product under its Tome brand -\- Tome Clearing Treatment includes a salicylic acid wipe with Dermata's Bioneedle™ mask and is expected to launch in H1 2027 for professionals and consumers -SAN DIEGO, CA / ACCESS Newswire / October 29, 2026 / , Inc. (Nasdaq:DRMA) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced enrollment of the first participant in a clinical trial evaluating Tome

Yahoo · Oct 15, 2026

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks:Stock Name Volume High Low Last Change Stardust Power Inc.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By